Inefficiency of insulin therapy to correct apolipoprotein A-I metabolic abnormalities in non-insulin-dependent diabetes mellitus

Atherosclerosis

Volumn 152, Issue 1, 2000, Pages 229-237

  Duvillard, Laurence ^a   Pont, Frédéric ^a   Florentin, Emmanuel ^a   Gambert, Philippe ^a   Vergès, Bruno ^a  

^a INSERM   (France)

Author keywords

Apolipoprotein A I; Apolipoprotein A II; Insulin; Kinetic study; Non insulin dependent diabetes mellitus; Stable isotope

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; CHOLESTEROL ESTER; GLIBENCLAMIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LEUCINE; LIPID TRANSFER PROTEIN; METFORMIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CATABOLISM; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN TREATMENT; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN ANALYSIS; STATISTICAL ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0034283518     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00473-6     Document Type: Article

References (38)

1. Taskinen M.R. Quantitative and qualitative lipoprotein abnormalities in diabetes mellitus. Diabetes Suppl 2. 41:1992;12-17.
2. Laakso M., Lehto S., Penttilä I., Pyörälä K. Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation. 88:1993;1421-1430.
3. O'Brien T., Nguyen T.T., Hallaway B.J., Hodge D., Bailey K., Kottke B.A. HDL subparticles and coronary artery disease in NIDDM. Atherosclerosis. 121:1996;285-291.
4. Syvänne M., Kahri J., Virtanen K.S., Taskinen M.R. HDL containing apolipoproteins A-I and A-II (LpA-I:LpA-II) as markers of coronary artery disease in men with non-insulin-dependent diabetes mellitus. Circulation. 92:1995;364-370.
5. Frénais R., Ouguerram K., Maugeais C., Mahot P., Maugère P., Krempf M., Magot T. High density lipoprotein apolipoprotein A-I kinetics in NIDDM: a stable isotope kinetic study. Diabetologia. 40:1997;578-583.
6. Golay A., Zech L., Shi M.Z., Chiou Y.A.M., Reaven G.M., Chen Y.D.I. High density lipoprotein (HDL) metabolism in non insulin dependent diabetes mellitus: measurement of HDL turnover using tritiated HDL. J. Clin. Endocrinol. Metab. 65:1987;512-518.
7. Pietzsch J., Julius U., Nitzsche S., Hanefeld M. In vivo evidence for increased apolipoprotein A-I catabolism in subjects with impaired glucose tolerance. Diabetes. 47:1998;1928-1934.
8. Taskinen M.R., Packard C.J., Sheperd J. Effect of insulin therapy on metabolic fate of apolipoprotein B-containing lipoproteins in NIDDM. Diabetes. 39:1990;1017-1027.
9. Taskinen M.R., Kuusi T., Helve E., Nikkilä E.A., Yki-Järvinen H. Insulin therapy induces antiatherogenic changes of serum lipoproteins in non insulin-dependent diabetes. Arteriosclerosis. 8:1988;168-177.
10. Paisey R., Elkeles R.S., Hambley J., Magill P. The effects of chlorpropamide and insulin on serum lipids, lipoproteins and fractional triglyceride removal. Diabetologia. 15:1978;81-85.
11. Agardh C.D., Nilsson-Ehle P., Schersten B. Improvement of the plasma lipoprotein pattern after institution of insulin treatment in diabetes mellitus. Diabetes Care. 5:1982;322-325.
12. Pont F., Duvillard L., Maugeais C., Athias A., Perségol L., Gambert P., Vergès B. Isotope ratio mass spectrometry, compared with conventional mass spectrometry in kinetic studies at low and high enrichment levels: application to lipoprotein kinetics. Anal. Biochem. 248:1997;277-287.
13. Shen D.C., Shien S.M., Fuh M.M.T., Wu D.A., Chen Y.D.I., Reaven G.M. Resistance to insulin-stimulated-glucose uptake in patients with hypertension. J. Clin. Endocrinol. Metab. 66:1988;580-583.
14. Vergès B., Rader D., Schaefer J., Zech L., Kindt M., Fairwell T., Gambert P., Brewer H.B. In vivo metabolism of apolipoprotein A-IV in severe hypertriglyceridemia: a combined radiotracer and stable isotope kinetic study. J. Lipid Res. 35:1994;2280-2291.
15. Pont F., Duvillard L., Vergès B., Gambert P. Development of compartmental models in stable isotope experiments: application to lipoprotein metabolism. Arterioscler. Thromb. Vasc. Biol. 18:1998;853-860.
16. Cobelli C., Toffolo G., Foster D.M. Tracer-to-tracee ratio for analysis of stable isotope tracer data: link with radioactive kinetic formalism. Am. J. Physiol. 262:1992;E968-E975.
17. Cobelli C., Toffolo G., Bier D.M., Nosadini R. Models to interpret kinetic data in stable isotope tracer studies. Am. J. Physiol. 253:1987;E551-E564.
18. Ikewaki K., Rader D.J., Schaefer J.R., Fairwell T., Zech L.A., Brewer H.B. Evaluation of apoA-I kinetics in humans using simultaneous endogenous stable isotope and exogenous radiotracer methods. J. Lipid Res. 34:1993;2207-2215.
19. Foster D.M., Barett P.H.R., Toffolo G., Beltz W., Cobelli C. Estimating the fractional synthetic rate of plasma apolipoproteins and lipids from stable isotope data. J. Lipid Res. 34:1993;2193-2205.
20. Braschi S., Masson D., Rostoker G., Florentin E., Athias A., Martin C., Jacotot B., Gambert P., Lallemant C., Lagrost L. Role of lipoprotein-bound NEFAs in enhancing the specific activity of plasma CETP in the nephrotic syndrome. Arterioscl. Thromb. Vasc. Biol. 17:1997;2559-2567.
21. Guyard-Dangremont V., Lagrost L., Gambert P., Lallemant C. Competitive enzyme-linked immunosorbent assay of the human cholesteryl ester transfer protein (CETP). Clin. Chim. Acta. 231:1994;147-160.
22. Fisher W.R., Venkatakrishnan V., Zech L.A., Hall C.M., Kilgore L.L., Stacpoole P.W., Diffenderfer M.R., Friday K.E., Sumner A.E., Marsh J.B. Kinetic evidence for both a fast and a slow secretory pathway for apolipoprotein A-I in humans. J. Lipid Res. 36:1995;1618-1628.
23. Batal R., Tremblay M., Krimbou L., Mamer O., Davignon J., Genest J., Cohn J.S. Familial HDL deficiency characterized by hypercatabolism of mature apoA-I but not proapoA-I. Arterioscl. Thromb. Vasc. Biol. 18:1998;655-664.
24. Zilversmit D.B. Atherogenesis: a postprandial phenomenon. Circulation. 60:1979;473-485.
25. Firth R.G., Bell P.M., Rizza R.A. Effects of tolazamide and exogenous insulin on insulin action in patients with non-insulin-dependent diabetes mellitus. N. Engl. J. Med. 314:1986;1280-1286.
26. Yki-Yärvinen H., Nikkila E., Eero H., Taskinen M.R. Clinical benefits and mechanisms of a sustained response to intermittent insulin therapy in type 2 diabetic patients with secondary drug failure. Am. J. Med. 84:1988;185-192.
27. UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-853.
28. Terry R.B., Yurgalevitch S., Thompson P.D. High-density apolipoprotein A-I and A-II kinetics in relation to regional adiposity. Metabolism. 41:1992;1386-1392.
29. Brinton E.A., Eisenberg S., Breslow J.L. Increased apo A-I and apo A-II fractional catabolic rate in patients with low high density lipoprotein-cholesterol levels with or without hypertriglyceridemia. J. Clin. Invest. 87:1991;536-544.
30. Brinton E.A., Eisenberg S., Breslow J.L. Human HDL cholesterol levels are determined by apoA-I fractional catabolic rate, which correlates inversely with estimates of HDL particle size: effect of gender, hepatic and lipoprotein lipases, triglyceride and insulin levels, and body fat distribution. Arterioscl. Thromb. 14:1994;707-720.
31. Lagrost L. The role of cholesteryl ester transfer protein and phospholipid transfer protein in the remodeling of plasma high density lipoproteins. Trends Cardiovasc. Med. 7:1997;218-224.
32. Sparks D.L., Davidson W.S., Lund-Katz S., Phillips M.C. Effect of the neutral lipid content of high density lipoprotein on apolipoprotein A-I structure and particle stability. J. Biol. Chem. 270:1995;26910-26917.
33. Braschi S., Neville T.A.M., Vohl M.C., Sparks D.L. Apolipoprotein A-I charge and conformation regulate the clearance of reconstituted high density lipoprotein in vivo. J. Lipid Res. 40:1999;522-532.
34. Horowitz B.S., Goldberg I.J., Merab J., Vanni T.M., Ramakrishnan R., Ginsberg H.N. Increased plasma and renal clearance of an exchangeable pool of apolipoprotein A-I in subjects with low levels of high density lipoprotein cholesterol. J. Clin. Invest. 91:1993;1743-1752.
35. Bagdade J.D., Lane J.T., Subbaiah P.V., Otto M.E., Ritter M.C. Accelerated cholesteryl ester transfer in non insulin-dependent diabetes mellitus. Atherosclerosis. 104:1993;69-77.
36. Jones R.J., Owens D., Brennan C., Collins P.B., Johnson A.H., Tomkin G.H. Increased esterification of cholesterol and transfer of cholesteryl ester to apo B-containing lipoproteins in type 2 diabetes: relationship to serum lipoproteins A-I and A-II. Atherosclerosis. 119:1996;151-157.
37. Mann C.J., Yen F.T., Grant A.M., Bihain B.E. Mechanism of plasma cholesteryl ester in hypertriglyceridemia. J. Clin. Invest. 88:1991;2059-2066.
38. Caixas A., Ordonez-Llanos J., de Leiva A., Payes A., Homs R., Perez A. Optimization of glycemic control by insulin therapy decreases the proportion of small dense LDL particles in diabetic patients. Diabetes. 46:1997;1207-1213.